Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.12
- Piotroski Score 3.00
- Grade Overweight
- Symbol (ZLAB)
- Company Zai Lab Limited
- Price $30.89
- Changes Percentage (1.41%)
- Change $0.43
- Day Low $30.56
- Day High $31.49
- Year High $36.60
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/11/2024
- Fiscal Year End N/A
- Average Stock Price Target $75.50
- High Stock Price Target $101.00
- Low Stock Price Target $50.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.50
- Trailing P/E Ratio -5.71
- Forward P/E Ratio -5.71
- P/E Growth -5.71
- Net Income $-334,620,000
Income Statement
Quarterly
Annual
Latest News of ZLAB
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Zai Lab Limited (ZLAB) Stock Price, News, Quote & History - Yahoo Finance
Zai Lab will showcase preclinical data of ZL-1503, a novel IL-13/IL-31 bispecific antibody for atopic dermatitis, at EADV Congress 2024. The presentation will cover the antibody's efficacy in treating...
By Yahoo! Finance | 1 month ago -
Zai Lab Limited (ZLAB): Top ADR Stock According to Hedge Funds
A list of Top 10 ADR Stocks To Buy by Hedge Funds features Zai Lab Limited (ZLAB) among other ADR stocks, emphasizing the importance of diversifying investments globally....
By Yahoo! Finance | 2 months ago -
Insider Selling: Chairperson & CEO Ying Du Sells Shares of Zai Lab Ltd (ZLAB)
Zai Lab Ltd is a biopharmaceutical company focused on innovative medicines for cancer, autoimmune, and infectious diseases. Recent insider selling trends, with 21 sells and 3 buys in the past year, al...
By Yahoo! Finance | 4 months ago
